Electron ionization (EI) mass spectra of some 3,4-disubstituted-1,2,4oxadiazin-5-ones and -thiones and 3,5-disubstituted 1,2,4-oxadiazin-6ones

Kalevi Pihlaja.^{a*} Sanna Heinonen,^a Olli Martiskainen,^a Hikmet Ağirbaş,^b and Nevin Arikan^c

^aDepartment of Chemistry, FI-20014 University of Turku, Finland. ^bDepartment of Chemistry, Kocaeli University, 41300 İzmit, Turkey ^cUludağ University, Science and Arts Faculty, Department of Chemistry, 16059, Bursa, Turkey *E-mail: <u>kpihlaja@utu.fi</u>*

Abstract

The EI mass spectra of 3,4-disubstituted-1,2,4-oxadiazin-5-ones 1-6 and -thiones 7,8 and 3,5disubstituted 1,2,4-oxadiazin-6-ones 9,10 were recorded and their fragmentation pathways solved and compared with each other. The fragmentation routes of 5-ones and 5-thiones do not differ very much from each other but compounds 9 and 10 behave differently as could be expected based on their lactone type structures. Only compounds 4-6 exhibit a loss of CO and compound 7 a loss of NO. The loss of a benzyl group dominates the behaviour of compounds 1 and 2 which showed only few additional fragmentations. Some earlier data on some 3,4-disubstituted-1,2,4-diazin-5-ones 11-13 and -thiones 14,15 have been reanalyzed and discussed in further detail.

Keywords: Electron ionization mass spectrometry, heterocyclic compounds, fragmentation pathways, reaction mechanism

Introduction

The title compounds possess a diversity of pharmacological activities,¹⁻⁵ e.g. antibacterial against some micro-organisms and yeast cultures.⁵ Only some low resolution EI data are available for a few 1,2,4-oxadiazin-5-ones^{6,7} and two 1,2,4-oxadiazin-5-thiones.⁶ No published mass spectrometric data was found for 1,2,4-oxadiazin-6-ones. Therefore we thought it interesting to discuss the mass spectrometric behaviour of the title compounds 1-10 (Figure 1) under electron ionization (EI) in detail. The syntheses of the studied compounds have been published earlier.^{5,8}

The low resolution EI mass spectra of some 3,4-disubstituted-1,2,4-oxadiazin-5-ones (cf. Figure 1: **11–13**) and -5-thiones (cf. Figure 1: **14** and **15**) have been reported.⁶ In another report some EI mass spectrometric data have been given for seven 2-(2-thienyl)-4-substituted-1,2,4-oxadiazin-5-

ones but the results do not appear to agree with the present data or with those given in Ref. $6.^7$ We have also reanalyzed the data for compounds 11-15.



Figure 1. Compounds 1–10 and 11–15 and typical fragmentations of 9 and 10.

Results and Discussion

3,4-Disubstituted-1,2,4-oxadiazin-5-ones (1-6)

Compounds 3 and 2. The fragmentation of compounds 1 and 2 is dominated by formation of the tropylium ion d (Table 1) which forms the base peak in both cases (Scheme 1). This also explains why their molecular ions are only moderately abundant as compared with those of compounds 3-6 (Tables 1 and 2) for which they form the base peaks. The loss of $C_2H_2NO_2^{\bullet}$ leads to medium strong ions a at m/z 195 both for 1 and 2. It is interesting that 2 gives a relatively abundant ion (RA 20.5%) c+1, $C_7H_8N^+$, at m/z 106 the parent ion of which is e+1 at m/z 210 (Table 1) which corresponds to loss of $C_2HO_2^{\bullet}$ from the molecular ion. Both of the former ions are missing from 1 which obviously must be due to the influence of the 2-pyridyl substituent when compared to the 4-pyridyl substituent in 2. Both compounds also show ions b+1 (2- or 4-PyNH⁺) and c-1, [(Bzl–H)N]⁺. The few further low mass ions are listed in Table 3.



Scheme 1. Typical fragmentations of compounds 1 and 2. The sites of fragmentations are also applicable for 3–8 and 11–15.

Compound	1	2	3	4	5	
R ¹	2-Py	4-Py	3-Py	4-Py	C ₆ H ₅	
\mathbf{R}^2	Bzl	Bzl	<i>p</i> -CH ₃ C ₆ H ₄	C_6H_5	p-CH ₃ C ₆ H ₄	
Fragment						
$\mathbf{M}^{+\bullet}$	267(19)	267(15)	267(100)	253(100)	266(100)	
a	$C_{13}H_{11}N_2^{+}$	$C_{13}H_{11}N_2^{+}$	$C_{13}H_{11}N_2^{+}$	$C_{12}H_9N_2^{+}$	$C_{14}H_{12}N^{+}$	
	195(18)	195(10)	195(8)	181(13)	194(9.5)	
b+1	$C_{6}H_{5}N_{2}^{+,a}$	$C_{6}H_{5}N_{2}^{+,a}$	$C_{6}H_{5}N_{2}^{+,a}$	$C_6H_5N_2^{+}$	$C_7H_5N^{+\bullet}(\mathbf{b})$	
	105(2)	105(6)	105(16)	105(24)	103(7)	
c+1	-	$C_7H_8N^+$	$C_7H_8N^+$	$C_6H_6N^+$	-	
	-	106(20.5)	106(6)	92(4)	-	
c	$C_7H_7N^{+\bullet,a}$	$C_7H_7N^{+\bullet,a}$	$C_7H_7N^{+\bullet,a}$	$C_6H_5N^{+\bullet}$	$C_7H_7N^{+\bullet}$	
	105(2)	105(6)	105(15)	91(25)	105(22)	
c-1	$C_7H_6N^{+,a}$	$C_7H_6N^{+,a}$	$C_7H_6N^{+,a}$	-	$C_7H_6N^+(also b+1)$	
	104(3)	104(4.5)	104(22)	-	104(19)	
d	$C_7H_7^+$	$\mathrm{C_7H_7}^+$	$C_7H_7^+$	$C_{6}H_{5}^{+}$	$C_{7}H_{7}^{+}$	
	91(100)	91(100)	91(95)	77(47)	91(61)	
e+1	-	$C_{13}H_{12}N_3^+$	$C_{13}H_{12}N_3^+$	$C_{12}H_{10}N_3^+$	$C_{14}H_{13}N_2^+$	
	-	210(5)	210(6)	196(10)	209(2)	
e	-	-	$C_{13}H_{11}N_3^{+\bullet}$	$C_{12}H_9N_3^{+\bullet}$	$C_{14}H_{12}N_2^{+\bullet}$	
	-	-	209(93)	195(90)	208(95)	
e-1	-	-	$C_{13}H_{10}N_3^+$	$C_{12}H_8N_3^+$	$C_{14}H_{11}N_2^+$	
	-	-	208(32)	194(5)	207(27)	
[M–CO] ^{+•}	-	-	$C_{14}H_{13}N_3O^{+\bullet}$	$C_{13}H_{11}N_3O^{+\bullet}$	$C_{15}H_{14}N_2O^{+\bullet}$	
f	-	-	239(12)	225(15)	238(4)	
f–1	-	-	$C_{14}H_{12}N_3O^+$	$C_{13}H_{10}N_3O^+$	-	
	-	-	238(4)	224(8)	-	
g	-	-	$C_8H_7N_2^{+,b}$	$C_7H_6N_2^{+\bullet,c}$	$C_8H_7N_2^{+,b}$	
	-	-	131(18)	118(28)	131(18)	
h	-	-	$C_8H_7NO^{+\bullet}$	-	$C_8H_7NO^{+\bullet}$	
	-	-	133(5)	-	133(3)	
h–1	-	-	$C_8H_6NO^+$	-	$C_8H_6NO^+$	
	-	-	132(12.5)	-	132(8)	
i	-	-	$C_8H_9N^{-\bullet}$	-	$C_8H_9N^{-\bullet}$	
• •	-	-	119(26)	-	119(17)	
i–1	-	-	-	$C_7H_6N^{\prime}$	-	
	-	-	_	104(5)	-	

Table 1. Main EI fragmentations [*m/z*(RA %)] of 3,4-disubstituted-1,2,4-oxadiazin-5-ones 1–5 at70 eV

 ${}^{a}C_{6}H_{5}N_{2}^{+}$ dominates. ${}^{b}Also C_{9}H_{9}N^{+\bullet}$. ${}^{c}g+1$.

Compound	<u>6</u>	7	8
\mathbf{R}^1	4-Pv	C ₆ H ₅	p-ClC ₆ H ₄
\mathbf{R}^2	<i>p</i> -CH ₃ OC ₆ H ₄	$p-CH_3C_6H_4$	<i>p</i> -CH ₃ C ₆ H ₄
Fragment	•	•	•
$M^{+\bullet}$	283(100)	282(63)	316(40)/318(16)
a	$C_{13}H_{11}N_2O^+$	$C_{14}H_{12}N^+$	$C_{14}H_{11}NCl^+$
	211(5.5)	194(11)	228(6)
b+1	$C_6H_5N_2^+$	$C_7H_5N^{+\bullet}(\mathbf{b})$	$C_7H_4NCl^{+\bullet}(\mathbf{b})$
	105(5)	103(9)	137(13)
c	$C_7H_7NO^{+\bullet}$	$C_7H_7N^{+\bullet}$	$C_7H_7N^{+\bullet}$
	121(13)	105(19)	105(13)
c–1	-	$C_7H_6N^+$ (also b+1)	-
	-	104(4.5)	-
d	-	$C_7H_7^+$	$C_7H_7^+$
	-	91(61)	91(41)
e	$C_{13}H_{11}N_3O^{+\bullet}$	$C_{14}H_{12}N_2^{+\bullet}$	$C_{14}H_{11}N_2Cl^{+\bullet}$
	225(34)	208(8)	242(5)
e-1	-	$C_{14}H_{11}N_2^+$	-
	-	207(9)	-
$[M-CO]^{+\bullet}$	$C_{14}H_{13}N_3O_2^{+\bullet}$	$[M-NO]^{+\bullet}(F)$	-
f	255(5)	252(5)	-
g	-	$C_8 H_7 N_2^{+,a}$	$C_{8}H_{7}N_{2}^{+,a}$
	-	131(9)	131(5)
h+1	-	$C_8H_8NS^+$	$C_8H_8NS^+$
	-	150(5)	150(4)
h	-	$C_8H_7NS^{+\bullet}$	$C_8H_7NS^{+\bullet}$
	-	149(100)	149(100)
h—1	-	$C_8H_6NS^+$	$C_8H_6NS^+$
	-	148(10)	148(7)
i	$C_8H_9NO^{+\bullet}$	$C_8H_9N^{+\bullet}$	-
	135(19)	119(5)	-
i–1	$C_8H_8NO^+$	$C_8H_8N^{+,b}$	$C_8H_8N^+$
	134(6)	118(24)	118(18)

Table 2. Main EI fragmentations [m/z(RA %)] of 3,4-disubstituted-1,2,4-oxadiazin-5-one **6** and 3,4-disubstituted-1,2,4-oxadiazin-5-thiones **7**–**8** at 70 eV

^aAlso C₉H₉N^{+•}. ^bContains 1/9 of C₇H₆N₂^{+•}.

Compound	Ions, <i>m/z</i> (RA %)
1	$C_5H_4N^+$, $C_6H_6^{+\bullet}$: 78(4.5); $C_5H_5^+$: 65(10); 51(5)
2	$C_5H_4N^+$, $C_6H_6^{+\bullet}$: 78(6); $C_5H_3N^{+\bullet}$, $C_6H_5^+$: 77(5); $C_5H_5^+$: 65(10); 51(8)
3	$[M-CH_{3}O]^{+}=C_{14}H_{10}N_{3}O^{+}:236(6); C_{7}H_{6}N_{2}^{+\bullet}=[e-C_{6}H_{5}N_{2}]^{+\bullet}:118(5); C_{6}H_{4}N^{+}:90(6);$
	$C_7H_5^+$: 89(7); $C_5H_5N^{+\bullet}$: 79(8.5); $C_5H_4N^+$: 78(29); $C_5H_3N^{+\bullet}$: 77(18); $C_6H_4^{+\bullet}$: 76(5);
	$C_{5}H_{5}^{+}$: 65(36); 64(4.5); 63(8); 52(9.5); 51(25); 50(8); 41(5.5); 39(7)
4	$C_{11}H_8N_2^{+\bullet} = [e - HCN]^{+\bullet}$: 168(4); 119(6), 117(6); $i-2 = C_7H_5N^{+\bullet}$: 103(12); $C_5H_4N^+$:
	78(23); 76(4.5); 65(5); 64(12); 63(5); 51(47); 50(8), 39(7)
5	$C_7H_5^+$: 89(5); $C_6H_6^{+\bullet}$: 78(9); $C_6H_5^+$: 77(24); 76(5); 65(23), 63(5), 52(5); 51(13); 39(10)
6	$C_{12}H_8N_3O^+ = [e-CH_3]^+: 210(76); C_{11}H_8N_3^+ = [e-CH_3-CO]^+: 182(5); C_9H_9NO^{+\bullet}:$
	$147(7) = [(M-C_5H_4N)-CNO]^+; C_7H_5N_2O^+: 133(5); C_7H_7O_2^+: 123(7); C_6H_4NO^+:$
	$106(10)$; $C_6H_6N^+$: 92(9); 80(5); 78(37); 77(11); 64(12); 63(7); 52(6); 51(21); 50(5)
7	$[M-C_{7}H_{5}NO]^{+\bullet} = C_{9}H_{9}NS^{+\bullet}: 163(12); C_{9}H_{8}NS^{+}: 162(5); C_{8}H_{9}S^{+}: 137(9);$
	$[M-CH_2O-C_8H_7N]^{+\bullet} = C_7H_5NS^{+\bullet}: 135(5); C_8H_6S^{+\bullet}: 134(7); C_8H_7NO^{+\bullet} = [M-h]^{+\bullet}:$
	133(5); $i-2$: C ₈ H ₇ N ^{+•} : 117(11); C ₈ H ₆ N ⁺ : 116(8); 90(7); 89(9); 77(16); 76(5), 65(37),
	63(7), 51(10); 45(5); 41(7); 39(13)
8	$[M-C_{7}H_{4}NOC1]^{+\bullet} = C_{9}H_{9}NS^{+\bullet}: 163(13); C_{9}H_{8}NS^{+}: 162(4); C_{8}H_{6}S^{+\bullet}: 134(6); i-2:$
	$C_8H_7N^{+\bullet}$ 117(9); $C_8H_6N^{+}$: 116(5.5); 90(6); 89(6); 65(26); 63(5); 51(5); 39(9)

Compounds 3–6. For all of them the molecular ion forms the base peak. The fragmentations of these compounds resemble very much each other although **6** gives fewer fragments than the other three compounds. In contrast to **1** and **2** they all exhibit ion **f**, $[M-CO]^{+\bullet}$, and **3** and **4** also the ion **f**–1 (Table 1). Like **1** and **2** they all show ions **a**, **b**+1 (**5** contains also ion **b** and in this case ion **b**+1 is identical with **c**–1) and **c** but in addition ions **d** (except **6**), **e**+1 (except **6**), **e**–1 (except **4**), **h** and **h**–1 (except **4** and **6**). Compounds **3** and **4** exhibit also ions **c**+1, **g** (also **5**) and **3** and **5** the ion **i** (Table 1, Schemes 1 and 2). Some further fragments for **3**–6 are shown in Tables 1 and 2. Some of them deserve a special mention. Only compound **3** gives the ion $[M-CH_3O]^+$ at m/z 236 (RA 6%) which is difficult to explain, but the total ion current and the B/E scan prove that it is formed from the molecular ion of **3**. Compounds **3** and **4** gave also another special ion, namely, $C_7H_6N_2^{+\bullet}$ at m/z 118 which corresponds to $[e-C_6H_5N]^{+\bullet}$ (RA 5%) for **3** and $[e-C_5H_3N]^{+\bullet}$ (RA 28%) for **4**, the latter being also equal to **g**+1.



Scheme 2. Typical fragmentations of compounds 3–8. The sites of fragmentations (h and i) are also applicable for 11–15.

Another special ion for **4** is $[e-HCN]^{+\bullet} = C_{11}H_8N_2^{+\bullet}$ at m/z 168 (RA 4%). Furthermore it gives the ions $C_7H_yN_2^{+(\bullet)}$ where y is equal to 5–7 from the ions e+1 and e (Tables 1 and 2). Compound **6** exhibits a few unique ions, namely formally $[e-CH_3-CO]^+ = C_{11}H_8N_3^+$ at m/z 182 (RA 5%), $C_8H_8NO^+$ at m/z 134 (RA 6%), $C_7H_5N_2O^+$ at m/z 133 (RA 5%) and $C_7H_7O_2^+$ at m/z 123 (RA 7%) (Tables 1 and 3). The latter ion is formed directly from the molecular ion, i.e. through a cyclization between the *ortho* position and the C=O oxygen assisted by the *p*-methoxy substituent (Scheme 3) and the consequent fragmentation gives the ion $C_7H_7O_2^+$ at m/z 123.



Scheme 3. The fragmentation of 6 through cyclization

3,4-Disubstituted-1,2,4-oxadiazin-5-thiones (7,8)

The fragmentations of these two compounds resemble very much those of compounds 1–6 although the effect of sulfur, i.e. the thione instead of the oxo function is clearly reflected in their fragmentation (Table 2). Compound 7 is the only one giving the ion F, $[M-NO]^{+\bullet}$, (RA 5%). As compared to the ions from 1–6, compounds 7 and 8 give a, b, c, d, e, g, h and h–1 and in addition h+1 the latter ions including sulfur instead of oxygen. Compound 7 gave also the ion c–1 which in this case is equal to b+1. The fragmentation routes are shown in Schemes 1 and 2. The ions $C_8H_xN^{+(\bullet)}$ (i, i–1 and i–2, Tables 2 and 3) were obtained via ions a, e as well as the ions m/z 149 and 163 both for 7 and 8. Compound 7 exhibits also the counter ions $C_9H_9NS^{+\bullet}$ (m/z 163) and $C_7H_5NO^{+\bullet}$ (m/z 119) and the ions $C_9H_8NS^+$ (m/z 162), $C_8H_9S^+$ (m/z 137), and $[M-h]^{+\bullet} = C_8H_7NO^{+\bullet}$ (m/z 133) (Table 3).

5-Isopropyl- (9) and 5-benzyl-1,2,4-oxadiazin-6-one (10)

The fragmentations of these two compounds (Figure 1, Table 4), possessing a lactone function, is very simple and differs completely from those of 5-ones 1–6 and 5-thiones 7 and 8 which in turn resemble fairly much each other. In both cases (Table 4) the base peak (ion A) corresponds to loss of the 5-substituent (i-Pr or Bzl). A weak ion $[M-CO_2]^{+\bullet}$ (B) is also present both for 9 and 10. The ion C at m/z 148 in turn corresponds to $[A-CO]^+$. Both compounds exhibit also the ion D, 2-PyCNH⁺, at m/z 105 and the ion E, 2-Py⁺, at m/z 78. Compound 10 shows also a relatively weak BzlCHN^{+•} ion at m/z 119 (Table 4).

Compound	R	$M^{+\bullet}$	Relevant ions, <i>m/z</i> (RA %)		
9	$(CH_3)_2CH$	219(7.5)	A : $[M-C_3H_7]^+ = C_8H_6N_3O_2^+: 176(100), $ B : $[M-CO_2]^{+\bullet} =$		
			$C_{10}H_{13}N_3^{+\bullet}$: 175(1), C: $[M-C_3H_7-CO]^+ = C_7H_6N_3O^+$: 148(12),		
			D : 2-PyCNH ⁺ = $C_6H_5N_2^+$: 105(21), E : 2-Py ⁺ = $C_5H_4N^+$: 78(23),		
			51(5.5)		
10	Bzl	267(1)	A : $[M-Bzl]^+ = C_8H_6N_3O_2^+$: 176(100), B : $[M-CO_2]^{+\bullet} =$		
			$C_{14}H_{13}N_3^{+\bullet}$: 223(3), C: $[M-BzI-CO]^+ = C_7H_6N_3O^+$: 148(4),		
			BzlCHN ^{+•} = $C_8H_9N^{+•}$: 119(4), D : 2-PyCNH ⁺ = $C_6H_5N_2^{+}$:		
			105(18); 104(5); $C_7H_7^+$: 91(16), E : 2-Py ⁺ = $C_5H_4N^+$: 78(19);		
			65(5), 51(6)		

Table 4. Significant fragments from 3-(2-pyridyl),5-isopropyl- 9 and -5-benzyl-1,2,4-oxadiazin-6-ones 10 at 70 eV

3,4-Disubstituted-1,2,4-diazin-5-ones (11–13) and -5-thiones (14,15)

Compounds 11–15.⁶ We have reanalyzed the data for these compounds (Schemes 1 and 2 and Table 5) based on the present results and they appear to be in general agreement with our observations for 1-8. The brief comments given in the original paper are mainly correct although there are also some shortcomings. First of all, the reported $[M+1]^+$ and $[M+2]^+$ peaks for 11–15 are due to the carbon and sulfur isotopes. The authors⁶ state that compounds **11–15** also exhibit peaks due to the nitrile oxide ions, R^1CNO^+ . This appears to be true only for 11 (m/z 57 (4%), 13 (m/z) 119(5%) and 15 (m/z 119(8%) since for 12 and 14 the peak at m/z 119 is due to the ¹³C equivalent of the ion **a**. However, the compounds studied in our work did not give nitrile oxide ions at all. The ions $R^1CN^{+\bullet}$ (b) and/or R^1CNH^+ (b+1) instead are relatively abundant for all compounds 11–15. Only compound 15 appears to give the ion c. As to the ion m/z 42 one should emphasize that in the case of 11 it can be either a or b+1 (Table 5). Also ions e-1, e, e+1, i and i-1 appear in most of 11–15, like in 1–8. The diaziridine ion, $[R^1CNR^2]^{+\bullet}$, is most abundant for 13, not for the thio analogs 14 and 15 as stated in Ref. 6. Based on its mass spectrum,⁶ compound 15 still appears to contain a substantial amount of 13 from which it was prepared⁹ as may be deduced from the appearance of the ion m/z 252 (RA 21%) which can be explained only by being due to the molecular ion of 13. Based on this observation we have corrected the relative abundances of those ions for 15 which also appear in the mass spectrum of 13.

Conclusions

The fragmentation routes of 3,4-disubstituted-1,2,4-diazine-5-ones and 5-thiones were proved to closely resemble each other. Those of 3,5-disubstituted-1,2,4-diazine-6-ones instead were substantially different and fairly simple which was anticipated based on their lactone type structures. Reanalysis of the low resolution reference data for some 3-phenyl-4-R-substituted 1,2,4-

diazine-5-ones (11–13: R = H, CH_3 , Ph) and -5-thiones (14,15: $R = CH_3$; Ph, respectively)⁶ indicated that they obeyed the rules confirmed in this paper but also needed some revision.

Experimental Section

General. All the studied compounds have been prepared earlier.^{5,8} 1,2,4-Oxadiazin-5-ones (1–6) were obtained from the reaction of the correspondingly *N*-substituted pyridine carboxamide oximes with chloroacetyl chloride in the presence of triethylamine.^{5,8} 1,2,4-oxadiazin-5-thiones (7,8) were obtained from the corresponding 5-ones by treating them with P_2S_5 .^{5,8} The reaction of 2-pyridine hydroxamic acid chloride hydrochloride with L-amino acid ester hydrochloride led in turn to the formation 1,2,4-oxadiazin-6-ones.⁵

Table 5. Some reanalyzed literature data [m/z(RA %)] for 3,4-disubstituted -1,2,4-oxadiazin-5-ones (11–13) and -5-thiones (14–15)⁶

Compound	11	12	13	14	15
\mathbf{R}^{1}	CH ₃	Ph	Ph	Ph	Ph
\mathbf{R}^2	Н	CH_3	Ph	CH ₃	Ph
Fragment					
$\mathbf{M}^{+\bullet}$	114(84)	190(100)	252(94)	206(100)	268(100)
а	$42(100)^{a}$	118(50)	180(10)	118(32)	180(14)
b	41(9)	103(25)	103(6)	103(20)	103(13)
b+1	$42(100)^{a}$	104(24)	104(4)	104(18)	104(30)
c	-	-	-	-	91(12)
d	-	-	$77(44)^{b}$	-	$77(55)^{b}$
e+1	57(4)	-	-	133(7)	-
e	56(3)	132(8)	194(100)	132(36)	194(22)
e-1	55(17)	131(3)	-	-	-
h	-	-	-	73(11)	135(52)
i	29(15)	-	105(16)	-	105(4)
i-1	-	-	$104(4)^{c}$	-	$104(30)^{c}$

^a**a** and **b+1** have the same elemental composition.

^bThis is most probably a combination of R^1 and R^2 since also **12** and **14** exhibit the ion $C_6H_5^+$ (RA 27 and 39%, respectively).

^cElemental composition the same as that of **b+1**.

The EI mass spectra were recorded on a VG ZABSpec mass spectrometer (VG Analytical, Division of Fisons, Manchester, UK), that was equipped with Opus V3.3X program package (Fisons Instruments, Manchester, UK). The ionization energy was 70 eV, accelerating voltage 8 kV and source temperature 160 °C. Direct insertion probe was used. Perfluorokerosene (PFK) was used for

calibration of the mass scale. The fragmentation pathways were confirmed by B/E-linked scans (1st FFR) for metastable ions. Also B^2/E -linked scans were used to clarify these pathways. The low resolution, B/E and B^2/E spectra were measured using resolution of 3000. To solve the ion structures the accurate masses (Tables 1 - 3) were determined practically for all ions by voltage scanning (10% valley definition) using 6,000-10,000 resolution.

References

- 1. Berkowictz, P. T.; Long, R. A.; Dea, P; Robins, R. K.; Mathews, T. R. J. Med. Chem. 1977, 20, 134.
- 2. 2. Van't Riet, B.; Elford, H. L. Drugs Future 1991, 16, 990.
- 3. Mishra, L.; Said, M. K.; Itokawa, H.; Takeya, K. Bioorg. Med. Chem. Lett. 1995, 3, 1241.
- 4. 4 Barbaric M.; Kraljvic, S.; Grce, M.; Zorc, B. Acta Pharm. 2003, 53, 176.
- 5. Arikan, N.; Sümengen, D.; Dülger, B. Turk. J. Chem. 2008, 32, 147.
- 6. Dürüst, Y.; Dürüst, N. Org. Mass Spectrom. 1992, 27, 833.
- 7. Dürüst, Y.; Altuğ, C.; Kiliç, F. Phosphorus, Sulfur, Silicon 2007, 182, 299.
- 8. Ağirbaş, H.; Kaya, A. G.; Aydoğdu. M. Phosphorous, Sulfur, Silicon 1999, 149, 39.
- 9. Dürüst, Y. Magn Reson. Chem. 1998, 36, 878.